Weisbrod Luke J, Thiraviyam Anand, Vengoji Raghupathy, Shonka Nicole, Jain Maneesh, Ho Winson, Batra Surinder K, Salehi Afshin
Department of Neurosurgery, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA.
Cancer Lett. 2024 May 28;590:216876. doi: 10.1016/j.canlet.2024.216876. Epub 2024 Apr 10.
Diffuse intrinsic pontine glioma (DIPG) is a childhood malignancy of the brainstem with a dismal prognosis. Despite recent advances in its understanding at the molecular level, the prognosis of DIPG has remained unchanged. This article aims to review the current understanding of the genetic pathophysiology of DIPG and to highlight promising therapeutic targets. Various DIPG treatment strategies have been investigated in pre-clinical studies, several of which have shown promise and have been subsequently translated into ongoing clinical trials. Ultimately, a multifaceted therapeutic approach that targets cell-intrinsic alterations, the micro-environment, and augments the immune system will likely be necessary to eradicate DIPG.
弥漫性脑桥内在型胶质瘤(DIPG)是一种脑干的儿童恶性肿瘤,预后很差。尽管最近在分子水平上对其有了进一步的认识,但DIPG的预后仍未改变。本文旨在综述目前对DIPG遗传病理生理学的认识,并强调有前景的治疗靶点。在临床前研究中已经对多种DIPG治疗策略进行了研究,其中一些已显示出前景,并随后转化为正在进行的临床试验。最终,可能需要一种多方面的治疗方法,该方法针对细胞内在改变、微环境并增强免疫系统,以根除DIPG。